The Patent Finder
DT

Decibel Therapeutics, Inc.

First filing 2018
OverviewNotableFeesChangesFamiliesPatent listSources & methods

11 patents currently held

4 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Feb 2039. from the record

Of the 4 now held by other companies, 3 name Regeneron Pharmaceuticals Inc. as their current owner, and 1 more name another party. Each row says which.

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Feb 2039
Next term end
6
Patent families

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
notable patents all others Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Jan 4, 2027
    The maintenance fee for Methods of Otoprotection Against Platinum-Based Antineoplastic Agents (US 11,690,870) comes due Jan 4, 2027. Unpaid by Jul 6, 2027, it lapses early.
  • 1 fee due Jul 2, 2027
    The maintenance fee for Hypertonic Pharmaceutical Compositions Containing an Anti-Platinum Chemoprotectant Agent (US 11,857,567) comes due Jul 2, 2027. Unpaid by Jan 3, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 1 of the patents on this record was granted since Aug 20, 2026

What they patent

The 5 largest of its 6 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.

Patents held now

Soonest term end first.
PatentTitleStatusExpiresConfidence
US 10,709,732Hypertonic Pharmaceutical Compositions Containing an Anti-Platinum Chemoprotectant Agent
In force
 · Medium confidence
In forceMedium confidence
US 10,813,947Methods of Otoprotection Against Platinum-Based Antineoplastic Agents
In force
 · High confidence
In forceHigh confidence
US 11,071,751Hypertonic Pharmaceutical Compositions Containing an Anti-Platinum Chemoprotectant Agent
In force
 · Low confidence
In forceLow confidence
US 11,690,870Methods of Otoprotection Against Platinum-Based Antineoplastic Agents
In force
 · Medium confidence
In forceMedium confidence
US 11,857,567Hypertonic Pharmaceutical Compositions Containing an Anti-Platinum Chemoprotectant Agent
In force
 · Low confidence
In forceLow confidence
US 12,653,838Methods of Otoprotection Against Platinum-Based Antineoplastic Agents
In force
 · Medium confidence
In forceMedium confidence
US 12,741,034Compositions and Methods for Treating Sensorineural Hearing Loss Using Otoferlin Dual Vector Systems
In force
 · High confidence
In forceHigh confidence
US 11,660,353Compositions and Methods for Treating Sensorineural Hearing Loss Using Otoferlin Dual Vector Systems
In force
 · High confidence
In forceHigh confidence
US 12,233,136Myosin 15 Promoters and Uses Thereof
In force
 · High confidence
In forceHigh confidence
US 12,534,739AAV1 Vectors and Uses Thereof for Treatment of Otic Indications
In force
 · High confidence
In forceHigh confidence
10 of 11 patents shown.
Pro members see all 11.
Pro members: see all 11 patents
Also on record, not counted in the 11: 4 patents in force now held by others · 26 applications pending · 2 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited